

Belumosudil (REZUROCK)

Criteria for Use

March 2024

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive belumosudil.

- Moderate or severe hepatic impairment (defined as Child-Pugh B or C)
- Unmanageable drug-drug-interaction
- Pregnancy
- Lactating
- Inability to monitor total bilirubin, AST and ALT at least monthly
- Inability to swallow tablets whole with a meal

Inclusion Criteria

All of the following criteria must be met.

- Care provided by a VA or VA Community Care hematology provider
- Eastern Cooperative Oncology Group Performance Status 0 - 2
- Diagnosis of chronic graft-versus-host disease (cGVHD) secondary to allogeneic hematopoietic stem cell transplant
- cGVHD disease progression after at least 2 prior lines of systemic therapy

Additional Inclusion Criteria

- For patients who can become pregnant: Pregnancy must be excluded prior to receiving belumosudil.
- For patients who can become pregnant and patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for one week after stopping treatment

Other Justification
